Alexandra Gomez-Arteaga, MD, on The Benefit of Orca-T Over PTCy HCT

“Currently for myeloablative conditioning, there's no real standard way of how we do GVHD prophylaxis. While last year the findings at ASH from the BMT1703 [study] showed that post-transplant cyclophosphamide, MMF and tacrolimus was better than tac/methotrexate in the reduced intensity conditioning. And now it's a new standard of care, everyone is using post-transplant cyclophosphamide in the reduced intensity conditioning. When we actually translate this to the myeloablative setting, there is no standard of care.”

Orca-T allogeneic cell therapy showed a benefit in non-relapse mortality, relapse free survival (RFS), and overall survival (OS) in treated patients with hematological malignancies compared with posttransplant cyclophosphamide (PTCy)-based myeloablative conditioning peripheral blood stem cell hematopoietic cell transplant, according to a retrospective analysis. GvHD free survival with Orca-T was also higher when compared with PTCy (73% vs 54%), and RFS and OS remained high at 2 years post Orca-T. The cell therapy is being evaluated in a randomized Phase 3 registrational trial (NCT05316701).

Data from the analysis were presented by Alexandra Gomez Arteaga, MD, Assistant Professor of Medicine and Anne Moore, MD, Clinical Scholar in Hematology-Oncology, Weill Cornell Medical College, at the 2024 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in San Antonio, Texas, February 21-24, 2024.

CGTLive spoke with Arteaga to learn more about Orca-T and the retrospective analysis. She described the rationale of the study and how there is no standard of care in the myeloablative setting to definitively compare Orca-T against. She went over how the analysis was put together and some of the findings.

View more coverage of the 2024 Tandem Meeting now.

REFERENCE

Gomez-Arteaga A, Oliai C, Patel SS, et al. A Retrospective Analysis Comparing Orca-T to Post-Transplant Cyclophosphamide Based Allogeneic Hematopoietic Cell Transplant in Patients with Matched Unrelated Donors Receiving Myeloablative Conditioning. Presented at: 2024 Tandem Meetings, February 21-24, San Antonio, Texas. Abstract #59